Free Trial

Tango Therapeutics Q4 2022 Earnings Report

Tango Therapeutics logo
$2.85 +0.07 (+2.52%)
As of 01/17/2025 04:00 PM Eastern

Tango Therapeutics EPS Results

Actual EPS
-$0.33
Consensus EPS
-$0.36
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Tango Therapeutics Revenue Results

Actual Revenue
$6.41 million
Expected Revenue
$6.60 million
Beat/Miss
Missed by -$190.00 thousand
YoY Revenue Growth
N/A

Tango Therapeutics Announcement Details

Quarter
Q4 2022
Time
N/A

Tango Therapeutics Earnings Headlines

Tango Therapeutics price target lowered to $8 from $16 at B. Riley
Vladimir Lenin was right…
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
See More Tango Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tango Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tango Therapeutics and other key companies, straight to your email.

About Tango Therapeutics

Tango Therapeutics (NASDAQ:TNGX), a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

View Tango Therapeutics Profile

More Earnings Resources from MarketBeat